Bcl-xL prevents peritoneal dialysis solution-induced leukocyte apoptosis

Perit Dial Int. 2008 Nov:28 Suppl 5:S48-52.

Abstract

Conventional glucose-containing peritoneal dialysis solutions (PDS) with a high glucose degradation product content accelerate leukocyte apoptosis and impair peritoneal defense. Mononuclear cells are less sensitive than neutrophils to PDS-induced apoptosis, suggesting that they may express antiapoptotic molecules. Since apoptosis induced by PDS requires Bax, we explored the role of an antiapoptotic protein of the same family, Bcl-xL, in PDS-induced apoptosis in cultured peripheral blood mononuclear cells and monocytic THP-1 cells. In these cells, conventional PDS decreased the expression of Bcl-xL protein with a temporal pattern compatible with their lethal effect. Inhibition of Bcl-xL also induced mononuclear cell apoptosis. A cell-permeable TAT-BH4 peptide that contains the BH4 domain of Bcl-xL prevented mononuclear cell apoptosis induced by PDS. These data suggest that Bcl-xL protects mononuclear cells from apoptosis induced by bioincompatible PDS and that Bcl-xL-like molecules should be explored to prolong leukocyte survival and potentiate peritoneal defense during peritonitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Apoptosis / physiology
  • Cell Culture Techniques
  • Dialysis Solutions / chemistry
  • Dialysis Solutions / pharmacology*
  • Glucose / pharmacology*
  • Humans
  • Leukocytes, Mononuclear / drug effects*
  • Leukocytes, Mononuclear / physiology
  • Peptides / pharmacology
  • Peritoneal Dialysis*
  • bcl-X Protein / antagonists & inhibitors
  • bcl-X Protein / physiology*

Substances

  • Dialysis Solutions
  • Peptides
  • TAT-BH4 peptide
  • bcl-X Protein
  • Glucose